Congenital Hyperinsulinism Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-30　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 158.4 Mn
2033 年預估規模: USD 321.6 Mn
年複合成長率 CAGR: 8.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-30頁數 152報告編號 CMI5329

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Congenital Hyperinsulinism Treatment Market, By Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI,HNF4A/HNF1A, etc.)), By Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothiazide, etc.)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months. Market Dynamics Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation. Key features of the study • This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market Market Segmentation • By Disease Type o KATP-HI o GDH-HI o GK-HI o Other (SCHAD HI,HNF4A/HNF1A, etc.) • By Drug Type o Diazoxide o Octreotide o Glucagon o Nifedipine o Other (Sirolimus, Chlorothiazide, etc.) • By Route of Administration o Oral o Parenteral • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Zealand Pharma A/S o Eli Lilly and Company o Xeris Pharmaceuticals, Inc. o Rezolute, Inc. o Hanmi Pharm.Co., Ltd. o Fresenius Kabi AG o Eiger BioPharmaceuticals. o Crinetics Pharmaceuticals, Inc. o AmideBio,LLC o Jolly Healthcare o e5 Pharma,LLC o Merck & Co.,Inc. o Novo Nordisk A/S o Amphaster Pharmaceuticals,Inc. o USV Private Limited o Teva Pharmaceutical Industries Ltd.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Disease Type  Market Snapshot, By Drug Type  Market Snapshot, By Route of Administration  Market Snapshot, By Distribution Channel  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Recent Developments o Acquisitions and Partnerships Scenario o Regulatory Scenario o Pricing Analysis o PEST Analysis 4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o KATP-HI  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o GDH-HI  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o GK-HI  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Other (SCHAD HI, HNF4A/HNF1A HI, etc.)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Diazoxide  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Octreotide  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Glucagon  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Nifedipine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Other (Sirolimus, Chlorothiazide, etc.)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Oral  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Parenteral  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2026 – 2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2021-2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o UK o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn) o North Africa o Central Africa o South Africa 9. Competitive Landscape o Zealand Pharma A/S  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Xeris Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Rezolute, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Hanmi Pharm.Co., Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Fresenius Kabi AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Eiger BioPharmaceuticals.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Crinetics Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o AmideBio,LLC  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Jolly Healthcare  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o e5 Pharma, LLC.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Novo Nordisk A/S  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Amphastar Pharmaceuticals.Inc,  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o USV Private Limited.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Teva Pharmaceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 10. Section o Research Methodology o About Us

提及公司

Zealand Pharma A/SEli Lilly and CompanyXeris Pharmaceuticals, Inc.Rezolute, Inc.Hanmi Pharm.Co., Ltd.Fresenius Kabi AGEiger BioPharmaceuticals.Crinetics Pharmaceuticals, Inc.AmideBio,LLCJolly Healthcaree5 Pharma,LLCMerck & Co.,Inc.Novo Nordisk A/SAmphaster Pharmaceuticals,Inc.USV Private LimitedTeva Pharmaceutical Industries Ltd.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們